Search
The World Health Organization recommends perennial malaria chemoprevention (PMC), generally using sulfadoxine-pyrimethamine (SP) to children at high risk of severe Plasmodium falciparum malaria. Currently, PMC is given up to age two in perennial transmission settings. However, no recommendation exists for perennial settings with seasonal variation in transmission intensity, recently categorized as 'sub-perennial'.
Malaria remains a leading cause of morbidity and mortality and is responsible for over 0.5 million annual deaths globally. During the first two decades of this century, scale-up of a range of tools was associated with significant reductions in malaria mortality in the primary risk group, young African children.
In recent decades, field and semi-field studies of malaria transmission have gathered geographic-specific information about mosquito ecology, behaviour and their sensitivity to interventions. Mathematical models of malaria transmission can incorporate such data to infer the likely impact of vector control interventions and hence guide malaria control strategies in various geographies.
This project forms a program of modelling to inform the Gate's Foundation’s malaria product development portfolio, otherwise known as the Integrated Portfolio Management (IPM) project.
At the American Society of Tropical Medicine and Hygiene (ASTMH) Annual Meetings in 2024 and 2025, our team convened stakeholder engagement sessions on next-generation malaria vaccines.
This project consists of two linked research programs, working to support malaria control and elimination using OpenMalaria: our in-house, open-source, malaria simulation tool.
Strep A causes a huge global burden of disease, from sore throats to rheumatic heart disease. Our team is developing a computer simulation model, OpenStrepA, to help researchers tackle this disease.
Julian is the Program Manager for the Global Disease Modelling team at The Kids Research Institute Australia.
Epke is a veterinarian that specializes in infectious disease control, and holds a PhD in human neglected tropical disease (NTD) control and elimination.
In this project, our team provides malaria vaccine impact predictions to inform vaccine investment strategies for Gavi, the Vaccine Alliance, and their partners.